Showing 2001-2010 of 5627 results for "".
- Your Patient Plans to Travel Despite COVID-19 Risk? Here’s the Latest CDC Guidance to Sharehttps://modernod.com/news/your-patient-plans-to-travel-despite-covid-19-risk-heres-the-latest-cdc-guidance-to-share/2478627/Make no mistake: Federal officials recommend the American public stay home over the upcoming holidays in order to stem the spread of the COVID-19 pandemic. Cases of COVID-19 are surging across the country and flooding—in some cases, overwhelming—hospitals, pushing many to postpone elective
- Supply Chain Snags Blamed For Cut to Pfizer COVID-19 Vaccine Rollout This Year: Reporthttps://modernod.com/news/supply-chain-snags-blamed-for-cut-to-pfizer-covid-19-vaccine-rollout-this-year-report/2478626/Pfizer and BioNTech expect to ship only half of the 100 million doses of COVID-19 vaccine they had originally targeted for worldwide delivery this year because of hurdles encountered with the supply chain, according to a report in The Wall Street Journal on Thursday. A person directly in
- Lumenis Launches Digital Duet SLT-YAG Platformhttps://modernod.com/news/lumenis-launches-digital-duet-digital-slt-yag-platform/2478540/Lumenis announced the launch of the Digital Duet SLT-YAG platform. The Digital Duet, which Lumenis describes as the first digital SLT-YAG system on the market, improves glaucoma treatment and posterior capsulotomy with the introduction of advanced digital and connectivity capabilities—rede
- Samsung Bioepis Announces 1-year Results From Phase 3 Study of SB11 Proposed Lucentis Biosimilarhttps://modernod.com/news/samsung-bioepis-announces-1-year-results-from-phase-3-study-of-sb11-proposed-lucentis-biosimilar/2478526/Samsung Bioepis announced 1-year results from the phase 3 study on SB11, a proposed biosimilar to Lucentis (ranibizumab), in patients with neovascular age-related macular degeneration (AMD). This data will be presented for the first time at the American Academy of Ophthalmology (AAO) 2020 Virtual
- Dell, HP, Lenovo and Acer to Announce New Eyesafe Products at the Blue Light Summit 2020https://modernod.com/news/dell-hp-lenovo-and-acer-to-announce-new-eyesafe-products-at-the-blue-light-summit-2020/2478378/Eyesafe, UnitedHealthcare Vision, and TÜV Rheinland Group announced the dates and registration details as well as the initial lineup of companies and thought leaders participating in the Blue Light Summit 2020. This year’s event will be held on Oct. 15, 2020. D
- Quantel Medical Launches Mosar High-Definition Imaging System for for Easyrethttps://modernod.com/news/quantel-medical-lauches-mosar-high-definition-imaging-system-for-for-easyret/2478247/Quantel Medical announced the launch of Mosar, a high-definition imaging system, on its yellow laser Easyret. Mosar features an HD camera, a screen and computer, and enhances the retinal laser treatment procedu
- New Licensing Agreement Accelerates the Development of IACTA Pharmaceuticals’ Novel Dry Eye Disease and Allergic Conjunctivitis Treatments in China and Southeast Asiahttps://modernod.com/news/new-licensing-agreement-accelerates-the-development-of-iacta-pharmaceuticals-novel-dry-eye-disease-and-allergic-conjunctivitis-treatments-in-china-and-southeast-asia/2478088/IACTA Pharmaceuticals and Zhaoke Ophthalmology Pharmaceutical (ZKO), a Hong Kong-based pharmaceutical company, announced they have entered into a definitive license agreement on the licensing of two of the company’s products, IC 265 for dry eye and IC 270 fo
- Rayner to Lower Carbon Footprint by More Than 800 Tons Over 5 Yearshttps://modernod.com/news/rayner-to-lower-carbon-footprint-by-more-than-800-tonnes-over-5-years/2478056/Rayner announced that changes to their manufacturing and packaging procedures will reduce CO2 greenhouse gas emissions by more than 800 tons over the next 5 years. The reduced CO2 greenhouse gas emissions are the result of three dedicated waste-reducing projects:
- CMS Increases Penalties Following Nearly 26K COVID-19 Nursing Home Deathshttps://modernod.com/news/cms-increases-penalties-following-nearly-26k-covid-19-nursing-home-deaths/2477852/The Trump administration has increased enforcement of states and nursing homes that have been repeat offenders for not following infection control practices, according to a FierceHealthcare
- TearClear Appoints Dr. Amir Shojaei Chief Development Officerhttps://modernod.com/news/tearclear-appoints-dr-amir-shojaei-chief-development-officer/2477803/TearClear Corp. announced the appointment of Amir Shojaei, PharmD, PhD, as Chief Development Officer. Over his 23-year career, Dr. Shojaei has focus